Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease (TANGO)

Conditions

Alzheimer's Disease

Phase II

What is the purpose of this trial?

Brief Summary:

To evaluate the safety and tolerability of BIIB092 in participants with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or with mild AD. To evaluate the efficacy of multiple doses of BIIB092 in slowing cognitive and functional impairment in participants with MCI due to AD or with mild AD. To evaluate the immunogenicity of BIIB092 after multiple doses in participants with MCI due to AD or with mild AD.

http://www.alzheimers.yale.edu

  • Trial with
    Biogen Idec, Inc.
  • Start Date
    10/24/2018
  • End Date
    07/20/2021

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

Trial Image

For more information about this study, contact:

Nina Diepenbrock

  • Last Updated
    04/23/2019
  • Study HIC
    #2000023510